# Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

> **NCT02981745** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Centaurus Biopharma Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Waldenstrom's Macroglobulinemia
- Mantle Zone Lymphoma Refractory/Recurrent
- Follicle Centre Lymphoma Diffuse
- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** CT-1530

## Key facts

- **NCT ID:** NCT02981745
- **Lead sponsor:** Centaurus Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-01
- **Primary completion:** 2018-09
- **Final completion:** 2018-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2017-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02981745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02981745, "Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02981745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*